HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients.

AbstractBACKGROUND:
Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation.
METHODS:
We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010.
RESULTS:
Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination.
CONCLUSION:
Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
AuthorsM Fernández-Ruiz, C Lumbreras, M P Arrazola, F López-Medrano, A Andrés, J M Morales, J R de Juanes, J M Aguado
JournalTransplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 17 Issue 2 Pg. 314-21 (Apr 2015) ISSN: 1399-3062 [Electronic] Denmark
PMID25728936 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Chemical References
  • Adjuvants, Immunologic
  • Immunosuppressive Agents
  • Influenza Vaccines
  • Squalene
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Adult
  • Aged
  • Cohort Studies
  • Female
  • Graft Rejection (epidemiology, pathology, prevention & control)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Influenza Vaccines (therapeutic use)
  • Influenza, Human (prevention & control)
  • Kidney Failure, Chronic (surgery)
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Prospective Studies
  • Retrospective Studies
  • Risk Factors
  • Squalene (therapeutic use)
  • Transplant Recipients

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: